Portfolio Lab

Corvus Pharmaceuticals, Inc.

  • Stock
  • Ticker CRVS
  • ISIN US2210151005
  • Nasdaq

Health care · Pharmaceuticals · USA

$9.67 −3.40%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Corvus Pharmaceuticals, Inc. since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

CRVSGlobal equities (VT)

$10,000 grew to $6,512. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −97.0% in 03/2023, measured from the peak in 03/2017. It took 106 months to get back to the old peak.

1-year return
+13.6%
5-year return p.a.
+22.5%
10-year return p.a.
−4.2%
Volatility p.a.
116.7%
Largest decline
−97.0%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Operating income-8.1-9.9-10-11-12-15-19-21
EBITDA-8.1-9.9-10-11-12-15-19-21
Net income-1215-8.0-10-12-14-18-20
Earnings per share-0.16-0.13-0.10-0.12-0.15-0.15-0.19-0.22
Balance sheet
Total assets6959898071253239224
Liabilities36109.28.79.9131416
Equity3349807261241225208
Cash8.75.0152.94.6401915
Cash flow
Operating cash flow-8.5-8.3-5.8-9.6-9.2-10-15-12
Capital expenditure–0.0-0.10.00.0-0.1-0.6-0.1
Free cash flow-8.5-8.3-5.9-9.6-9.2-10-16-12

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2024 at +204.0%, weakest 2022 at −64.7%. 4 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
5 Nov 2026−$0.22
6 Aug 2026−$0.19
7 May 2026−$0.15
12 Mar 2026−$0.15
4 Nov 2025−$0.12
7 Aug 2025−$0.10
8 May 2025−$0.13
25 Mar 2025−$0.16
12 Nov 2024−$0.60
6 Aug 2024−$0.07
7 May 2024−$0.12
19 Mar 2024−$0.13

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€739m
Market cap in trading currency
$816m
Enterprise value
$613m
P/E
–
P/S
–
P/B
3.92
EV/Sales
–
EV/EBITDA
–
Earnings yield
–
FCF yield
-5.9%

Results (last four quarters)

Revenue
–
Gross profit
–
EBITDA
−$67.6m
Net income
−$64.3m
Earnings per share
−$0.71
Revenue per share
–
Revenue growth
–
Earnings growth
–

Profitability

Gross margin
–
Operating margin
–
Net margin
–
Return on equity
-45.9%
Return on assets
-28.7%

Balance sheet and cash flow

Cash
$203m
Cash per share
$2.41
Financial debt
–
Debt/equity %
–
Current ratio
13.38
Book value per share
$2.47
Operating cash flow
−$47.2m
Free cash flow
−$47.9m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
–
Ex-dividend date
–

Shares and trading

Shares outstanding
84.4m
Volume
927,500
Avg. volume 3 months
1.04m
Relative volume
0.9

Price and technicals

Price
$9.67
1 day
−3.4%
52-week high
$25.52
52-week low
$6.50
Distance to 52-week high
−62.1%
Distance to 52-week low
+48.8%
Distance to 50-day line
−10.8%
Distance to 200-day line
−29.6%
RSI (14)
40
Volatility 1M
66.9%

Performance

1 week
−9.1%
1 month
−9.2%
3 months
−31.4%
6 months
−23.3%
YTD
+25.6%
1 year
+8.7%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has CRVS performed since 11/2016?

$10,000 grew to $6,512 by 20 Nov 2026, which is −4.2% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is CRVS?

Volatility was 116.7% per year, measured on monthly returns. The largest decline from a peak was −97.0%, with the low in 03/2023.

How does CRVS compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, CRVS returned −4.2% at 116.7%. The correlation of monthly returns was 0.18; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Corvus Pharmaceuticals, Inc. (CRVS): Return and risk